ArticleTurkish journal of medical sciences2026
Involvement of SWAP-70 in proteolipid protein-induced experimental autoimmune encephalomyelitis.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. Studies have shown that B cells may play an important role in the induction and progression of MS. Switch-associated protein 70 (SWAP-70) is a signal transduction molecule abundantly expressed in B cells and involved in B-cell polarization, directed migration, endothelial cell adhesion, and tissue homing. B-cell stimuli increase its expression. SWAP-70 has been implicated in the pathogenesis of autoimmune disorders, including MS. This study aims to investigate the effects of acquired SWAP-70 inhibition on immune cell subsets in experimental autoimmune encephalomyelitis (EAE). Materials and methods: EAE was induced in Swiss James Lambert mice by immunization with proteolipid protein. EAE-induced mice were treated with either SWAP-70 short hairpin ribonucleic acid (shRNA) or nontargeting scrambled shRNA. Control PLP-immunized and non-PLP-immunized mice received saline treatment. The model was established by immunofluorescence studies demonstrating spinal cord demyelination and immune cell infiltration. Ratios of lymph node cell subsets were assessed by flow cytometry at termination. Results: All PLP-immunized mice showed clinical signs of EAE and demyelination and CD8+ T-cell/macrophage infiltration at spinal cord sections. SWAP-70 shRNA-treated mice showed significantly higher average clinical EAE scores than the other groups. SWAP-70 shRNA-treated mice showed significantly higher lymph node CD19+CXCR5+CD21+ follicular B-cell ratios than other groups, whereas ratios of other effector B-cell and T-cell subsets were comparable among groups. Conclusion: SWAP-70 appears to have an autoimmunity-suppressing effect in the PLP-EAE model, likely mediated by inhibiting follicular B cells. These findings propose a novel mechanism by which SWAP-70 might be involved in autoimmunity and endorse SWAP-70 as a potential target in novel MS-treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.